Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis-Reference-Cited by-同舟云学术

Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis

Published:2016-11-22 Issue:2 Volume:264 Page:284-294
ISSN:0340-5354
Container-title:Journal of Neurology
language:en
Short-container-title:J Neurol

Author:

Prosperini Luca^ORCID,Saccà Francesco,Cordioli Cinzia,Cortese Antonio,Buttari Fabio,Pontecorvo Simona,Bianco Assunta,Ruggieri Serena,Haggiag Shalom,Brescia Morra Vincenzo,Capra Ruggero,Centonze Diego,Di Battista Giancarlo,Ferraro Elisabetta,Francia Ada,Galgani Simonetta,Gasperini Claudio,Millefiorini Enrico,Mirabella Massimiliano,Pozzilli Carlo

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

http://link.springer.com/content/pdf/10.1007/s00415-016-8343-5.pdf

Reference34 articles.

1. Ransohoff RM, Hafler DA, Lucchinetti CF (2015) Multiple sclerosis-a quiet revolution. Nat Rev Neurol 11:134–142

2. Caon C, Din M, Ching W et al (2006) Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 13:471–474

3. Carra´ A, Onaha P, Luetic G et al (2008) Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol 15:386–393

4. Limmroth V, Rolf M, Zettl UK et al (2007) Quality assessment in multiple sclerosis quality (QUASIMS): a comparison of different therapies for relapsing-remitting multiple sclerosis. J Neurol 254:67–77

5. Prosperini L, Borriello G, De Giglio L et al (2011) Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? BMC Neurol 11:26

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Literature review and meta-analysis of natalizumab therapy for the treatment of highly active relapsing remitting multiple sclerosis in the ‘suboptimal therapy’ patient population;Journal of the Neurological Sciences;2024-09

2. Pediatric-onset Multiple Sclerosis treatment: a multicentre observational study comparing natalizumab with fingolimod;Journal of Neurology;2024-08-23

3. Effects of fingolimod on focal and diffuse damage in patients with relapsing–remitting multiple sclerosis – The “EVOLUTION” study;Journal of Neurology;2024-07-29

4. Safety and efficacy of extended versus standard interval dosing of natalizumab in multiple sclerosis patients: a systematic review and meta-analysis;Acta Neurologica Belgica;2024-03-08

5. Visualizing the target estimand in comparative effectiveness studies with multiple treatments;Journal of Comparative Effectiveness Research;2024-02